A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participant
AZD0292 is a bispecific IgG1k mAb being evaluated for the prevention of exacerbations in bronchiectasis patients chronically colonized with PsA.
| Condition(s) | Bronchiectasis With Pseudomonas Aeruginosa Colonization |
|---|---|
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Summary | AZD0292 is a bispecific IgG1k mAb being evaluated for the prevention of exacerbations in bronchiectasis patients chronically colonized with PsA. |
| Who can participate | Inclusion Criteria: 1. Participant must be ≥ 12 years of age at the time of signing the informed consent/assent 2. Weight ≥ 35 kg 3. Bronchiectasis diagnosed by a physician and confirmed by CT demonstrating abnormal bronchial dilation in ≥ 1 lobe. Note: A historical CT scan within the past 5 years is acceptable. If not available, a CT scan should be conducted at screening to confirm eligibility. 4. Participants who are receiving appropriate standard of care therapy per local guidelines and have a documented history of ≥ 2 moderate exacerbations or ≥ 1 severe exacerbation in the preceding 12 months requiring antibiotics 5. Participants who are clinically stable and free from an exacerbation of bronchiectasis for 4 weeks prior to randomization 6. Participants with pre- or post-bronchodilator |
| Ages | 12 Years |
| Sex | All |
| Lead sponsor | AstraZeneca |
| Locations | Orange, California, United States; San Francisco, California, United States; Denver, Colorado, United States; Washington D.C., District of Columbia, United States; Jacksonville, Florida, United States; Miami Lakes, Florida, United States (+179 more sites) |
| Start date | 2025-11-06 |
| NCT ID | NCT07088926 |
| Official listing | https://clinicaltrials.gov/study/NCT07088926 |